产品
编 号：F051000
分子式：C21H25F6N5O5
分子量：541.44
分子式：C21H25F6N5O5
分子量：541.44
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1159840-61-5
产品详情
生物活性：
Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10?μM.
体内研究：
Dendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) improves the anti-tumor effects of NK cells.Animal Model:Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)
Dosage:1 mg/kg per mouse
Administration:i.p.; daily for 7 days
Result:Significantly suppressed the growth of human HepG2 liver carcinoma xenografts.
体外研究：
Gardiquimod diTFA (6-60?μM ) significantly inhibits cDNA synthesis by HIV-1 reverse transcriptase.
Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10?μM.
体内研究：
Dendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) improves the anti-tumor effects of NK cells.Animal Model:Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)
Dosage:1 mg/kg per mouse
Administration:i.p.; daily for 7 days
Result:Significantly suppressed the growth of human HepG2 liver carcinoma xenografts.
体外研究：
Gardiquimod diTFA (6-60?μM ) significantly inhibits cDNA synthesis by HIV-1 reverse transcriptase.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备